View Financial HealthGilead Sciences 배당 및 자사주 매입배당 기준 점검 5/6Gilead Sciences 수익으로 충분히 충당되는 현재 수익률 2.49% 보유한 배당금 지급 회사입니다.핵심 정보2.5%배당 수익률0.9%자사주 매입 수익률총 주주 수익률3.4%미래 배당 수익률2.2%배당 성장률7.5%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향46%최근 배당 및 자사주 매입 업데이트Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025Nov 01Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updates모든 업데이트 보기Recent updatesGilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more updateGilead Sciences, Inc., Annual General Meeting, Apr 30, 2026Mar 23Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026Feb 11+ 1 more updateFda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026Jan 28Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 TrialDec 15Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 StudyNov 07+ 1 more updateGilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025Nov 01Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025Oct 31Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more updateGilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025Oct 14Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 10Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updatesGilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more updateGilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025Jul 14Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more update지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: GILD 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: GILD 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Gilead Sciences 배당 수익률 vs 시장GILD의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GILD)2.5%시장 하위 25% (CA)1.6%시장 상위 25% (CA)5.4%업계 평균 (Biotechs)2.6%분석가 예측 (GILD) (최대 3년)2.2%주목할만한 배당금: GILD 의 배당금( 2.49% )은 Canadian 시장에서 배당금 지급자의 하위 25%( 1.64% )보다 높습니다.고배당: GILD 의 배당금( 2.49% )은 Canadian 시장에서 배당금 지급자의 상위 25%( 5.38% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 46.2% )로 GILD 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 43.1% )로 GILD 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 18:47종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gilead Sciences, Inc.는 66명의 분석가가 다루고 있습니다. 이 중 27명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David ToungArgus Research CompanyBrian SkorneyBairdEmily FieldBarclays63명의 분석가 더 보기
Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updates
Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02
Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more update
Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23
Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17
Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06
Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22
Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18
Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20
Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18
Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13
Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23
Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22
Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more update
Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16
Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26
Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updates
Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more update
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23
Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more update